Most laser complications in Black skin are not random. They are the predictable result of using a wavelength, fluence, or pulse duration that interacts badly with melanin-rich epidermis. The dermatology literature has documented this for over two decades. The question is not whether lasers can be used safely on Fitzpatrick IV–VI skin — they can — but which specific wavelengths, at which settings, with which pre-treatment protocols, produce results without triggering post-inflammatory hyperpigmentation that can take months to resolve and look worse than the original problem.
Here is what the evidence says about laser resurfacing in Black skin: which wavelengths are appropriate, which should be avoided, what device settings reduce risk, and why the provider's experience with skin of color matters more than the device itself.
The core problem: melanin as a competing chromophore
Laser resurfacing works by directing energy at a specific target — a chromophore — in the skin. For resurfacing, the target is water. For hair removal, the target is melanin in the hair shaft. For vascular lesions, the target is hemoglobin. The specificity of the chromophore interaction is what makes lasers useful: the right wavelength hits the target while sparing surrounding tissue.
In darker skin, the epidermis contains more melanin, packed into larger melanosomes. Melanin absorbs broadly across the visible and near-infrared spectrum — its absorption is highest at shorter wavelengths and decreases progressively as wavelength increases. This creates a problem: when a laser wavelength that melanin absorbs well is used on dark skin, the energy is absorbed in the epidermis before it reaches the deeper target. The epidermis heats. The melanocytes respond with inflammation. And post-inflammatory hyperpigmentation follows.
The clinical consequence is straightforward. Shorter wavelengths — ruby (694 nm), alexandrite (755 nm), IPL (broadband 500–1200 nm), and diode (800–810 nm) — are absorbed more strongly by epidermal melanin. In Fitzpatrick IV–VI, these wavelengths cause thermal injury to the epidermis at energy levels that would be safe in lighter skin. Longer wavelengths — Nd:YAG at 1064 nm, erbium:glass at 1540 nm, and 1550 nm — penetrate through the epidermis with less melanin absorption and reach deeper targets more safely. This is not a theoretical concern. It is the single most important variable in whether a laser treatment helps or harms a patient with dark skin.
Which wavelengths are safer for Fitzpatrick IV–VI
Nd:YAG 1064 nm: the gold standard for hair removal, with a strong safety record
The 1064 nm Nd:YAG laser has the longest clinically available wavelength for dermatologic use, and it is the consensus gold standard for laser hair removal in Fitzpatrick IV–VI. Its long wavelength means minimal absorption by epidermal melanin and deep penetration into the dermis — exactly what is needed to reach the hair bulb while sparing the pigmented epidermis above it.
Multiple reviews confirm that Nd:YAG 1064 nm produces lower rates of hyperpigmentation, hypopigmentation, and scarring in dark skin compared to ruby, alexandrite, or diode lasers. A 2003 review by Battle and Hobbs in Dermatologic Clinics established that the Nd:YAG's longer wavelength and the availability of longer pulse durations — which allow epidermal cooling between pulses — make it the safest laser for hair removal in Fitzpatrick V–VI. The StatPearls review on laser Fitzpatrick skin type recommendations concurs: Nd:YAG is the first-line recommendation for Fitzpatrick IV–VI across hair removal and several dermatologic indications.
For resurfacing specifically, Nd:YAG is not a primary tool — it targets melanin and hemoglobin rather than water. But its safety profile in dark skin is the reference point against which other wavelengths are judged.
Non-ablative fractional lasers (1540 nm, 1550 nm): the best evidence for acne scarring in dark skin
Non-ablative fractional lasers create microscopic columns of thermal injury in the dermis without removing the epidermis. The 1540 nm erbium:glass and 1550 nm wavelengths target water, but at energy levels that heat rather than vaporize tissue. Because the epidermis is preserved and the thermal columns are spaced apart, healing is faster and the inflammatory response is muted compared to ablative resurfacing.
The strongest evidence for safe laser resurfacing in Fitzpatrick IV–VI comes from this category. A 2016 randomized controlled trial by Alexis et al. published in Dermatologic Surgery specifically evaluated nonablative 1550 nm fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV–VI. The study found that the treatment was safe and efficacious, with PIH that was self-limited — it resolved without intervention in the majority of cases. This is one of the few RCTs designed specifically for skin of color, and it provides the most direct evidence that non-ablative fractional resurfacing at this wavelength can be performed safely in the population most vulnerable to pigment complications.
A 2024 review by Aggarwal, Rossi, and Tsoukas in Dermatologic Surgery (via PMC) examined fractional nonablative lasers across darker skin phototypes. The review confirmed that 1540 nm and 1550 nm wavelengths have favorable safety profiles in Fitzpatrick IV–VI, and emphasized that lower treatment densities — fewer microthermal zones per square centimeter — are a critical variable for reducing PIH risk. The density adjustment is not a minor tweak. It is the primary lever that providers use to make these lasers safe for dark skin.
Ablative CO2 fractional: effective, but with significantly elevated PIH risk
Fractional CO2 (10,600 nm) resurfacing is one of the most effective treatments for deep acne scars and significant photoaging. The wavelength targets water with high absorption, producing deep ablation and thermal coagulation that drives neocollagenesis. In Fitzpatrick I–III, it is a first-line option.
In Fitzpatrick IV–VI, the situation is different. The deeper tissue injury and broader thermal damage zone produced by CO2 create a more intense inflammatory response, and that inflammation triggers melanocyte activation in patients whose melanocytes are already more reactive. A 2025 narrative review in PMC on noninvasive cosmetic treatments for Fitzpatrick IV–VI recommends avoiding ablative lasers in darker skin due to the significantly increased risk of both PIH and hypopigmentation. The recommendation is not absolute — experienced providers do use fractional CO2 in Fitzpatrick IV and sometimes V — but it reflects the consensus that the risk-benefit ratio is unfavorable compared to non-ablative alternatives.
When fractional CO2 is used in darker skin, the settings must be conservative: lower fluence, lower density (typically under 20% fractional coverage), and fewer passes. The provider must be prepared to manage PIH, which is common enough in this context that it should be discussed as an expected possibility rather than a rare complication.
Er:YAG 2940 nm: less thermal damage, potentially safer
The Er:YAG laser at 2940 nm has a water absorption coefficient roughly 16 times higher than CO2, which means it ablates tissue very efficiently with minimal residual thermal damage. The zone of thermal injury beyond the ablation front is 20–50 μm for Er:YAG compared to up to 200 μm for CO2. Less thermal spread means less inflammation, which means lower PIH risk.
Er:YAG is considered potentially safer than CO2 for darker skin for this reason, but it still requires caution. It is an ablative laser, and ablation in Fitzpatrick V–VI always carries pigment risk. The evidence base for Er:YAG specifically in Black skin is smaller than for non-ablative fractional lasers, and most recommendations are extrapolated from the general principle that less thermal damage equals less PIH.
Hybrid fractional lasers: emerging evidence
Hybrid fractional lasers combine two wavelengths simultaneously — typically an ablative wavelength and a non-ablative wavelength — to deliver both ablation and coagulation in a single pass. The Sciton Halo, which combines 2940 nm (Er:YAG) and 1470 nm (diode), is the most widely used platform. ClinicalTrials.gov lists NCT05362929, a study examining the efficacy and tolerability of a hybrid fractional laser specifically for acne scars in patients with skin of color (Fitzpatrick IV–V). The study is ongoing, and published results are not yet available. The rationale is sound — the hybrid approach may allow ablative-level results with non-ablative-level thermal injury — but the evidence for this specific application in dark skin is preliminary.
What to avoid in Fitzpatrick IV–VI
Not every laser is appropriate for dark skin, and some are clearly contraindicated.
IPL (intense pulsed light). IPL emits a broad spectrum of light (typically 500–1200 nm) rather than a single wavelength. The broadband output includes significant energy at wavelengths absorbed by melanin. In Fitzpatrick V–VI, the non-selective heating of epidermal melanin makes IPL unsafe for most indications. The 2025 PMC review explicitly states that IPL is not recommended for Fitzpatrick V–VI. Even in Fitzpatrick IV, IPL carries substantial PIH risk if fluence is too high or pulse duration is too short.
Diode laser (800–810 nm). Used primarily for hair removal, the diode laser has been associated with a dramatically higher PIH rate in darker-skinned patients. The 2025 PMC narrative review notes that diode lasers demonstrate a 10-fold increase in PIH rates in darker-skinned patients compared to Nd:YAG. The wavelength is absorbed more strongly by epidermal melanin than 1064 nm, and the shorter pulse durations typical of diode devices do not allow adequate epidermal cooling. For hair removal in Fitzpatrick IV–VI, Nd:YAG is the safer choice by a wide margin.
Ruby (694 nm) and alexandrite (755 nm). These shorter wavelengths are absorbed strongly by melanin. They are used for pigmented lesions and hair removal in lighter skin, but they are contraindicated for most applications in Fitzpatrick V–VI due to unacceptable PIH risk. In Fitzpatrick IV, they may be used with extreme caution for specific indications by experienced providers, but they are never first-line.
Settings that reduce risk
The wavelength is the starting point. The device settings determine whether a safe wavelength actually produces a safe outcome.
Lower fluence (energy density). Higher energy produces more tissue injury and more inflammation. In dark skin, the threshold for triggering PIH is lower. Starting at conservative fluence and titrating upward based on response is standard practice for Fitzpatrick IV–VI.
Longer pulse durations. Longer pulses deliver energy more slowly, which allows the epidermis to cool between pulses via the cooling mechanism (contact cooling, cryogen spray, or forced cold air). This reduces epidermal thermal injury without compromising dermal effect. The Nd:YAG's safety in dark skin is partly attributable to the availability of long pulse durations.
Lower treatment densities for fractional lasers. Density refers to the number of microthermal zones per unit area. Higher density means more tissue treated per pass but also more total inflammation. In Fitzpatrick IV–VI, lower density is one of the most effective ways to reduce PIH. The Alexis et al. 2016 RCT used density adjustments as part of the safety protocol. Aggarwal et al. (2024) identified density as the primary setting variable for safe fractional resurfacing in darker skin.
Epidermal cooling is critical. All modern laser platforms intended for use on darker skin incorporate some form of epidermal cooling — contact cooling plates, cryogen spray (dynamic cooling), or forced cold air. Cooling protects the epidermis by lowering its temperature before and during the laser pulse, reducing melanin-mediated thermal injury. If a device does not have integrated cooling, it should not be used on Fitzpatrick IV–VI skin.
Test spots. Treating a small area (1–2 cm²) at the planned settings and waiting 48–72 hours to assess response is standard practice for Fitzpatrick V–VI. A test spot reveals how an individual patient's skin will respond before committing to a full-face or large-area treatment. It adds time and cost, but it also prevents the kind of widespread PIH that results from treating aggressively on untested skin.
Pre-treatment protocols
Pre-treatment aims to suppress melanocyte activity before the inflammatory insult of the laser, reducing the likelihood that the procedure triggers PIH.
Hydroquinone 4% for 2–4 weeks before treatment. Hydroquinone inhibits tyrosinase, the rate-limiting enzyme in melanin synthesis. The standard pre-treatment protocol for Fitzpatrick V–VI includes 2–4 weeks of hydroquinone 4% applied twice daily. However, the evidence is mixed. A 1999 study by West et al. found no benefit of pre-treatment with glycolic acid 10%, hydroquinone 4%, and tretinoin 0.025% before full-field CO2 resurfacing — the pre-treated group did not have lower PIH rates than the control group. This may reflect the intensity of full-field CO2 injury overwhelming any pre-treatment benefit, or it may reflect limitations of that specific regimen. Current clinical practice continues to recommend pre-treatment for fractional and non-ablative procedures in dark skin, but the practice rests more on expert consensus than on strong RCT data.
Stop retinoids 3–7 days before treatment. Tretinoin and other retinoids increase cell turnover and thin the stratum corneum, which can increase laser penetration unpredictably. Most protocols recommend stopping retinoids 3–7 days before laser treatment. Some dermatologists recommend stopping all actives — including hydroquinone — 3 days before resurfacing to ensure the skin barrier is intact.
Strict sun protection. UV exposure stimulates melanocytes and increases PIH risk. Patients should avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily for at least 4 weeks before treatment. Tanned skin should not be treated.
Post-treatment PIH management
PIH after laser resurfacing typically appears 3–6 weeks after the procedure — well after the initial redness and peeling have resolved. This delayed onset means patients may believe the treatment went smoothly, only to discover new darkening weeks later.
The good news is that most PIH from non-ablative fractional lasers is self-limited. The Alexis et al. RCT found that PIH after 1550 nm fractional treatment in Fitzpatrick IV–VI resolved within 1–6 months without specific intervention. The American Academy of Dermatology notes that early treatment of PIH can hasten resolution, and clinical practice supports initiating treatment rather than waiting passively.
Post-treatment hydroquinone 4%. If PIH develops, hydroquinone 4% applied twice daily can accelerate fading. Courses of 2–3 months with breaks are recommended to reduce the risk of exogenous ochronosis (paradoxical darkening from chronic hydroquinone use).
Tretinoin and azelaic acid. Tretinoin increases melanin turnover and enhances hydroquinone penetration. Azelaic acid 15–20% is an alternative for patients who cannot tolerate hydroquinone, with both anti-melanogenic and anti-inflammatory properties. A triple-combination cream containing hydroquinone, tretinoin, and a mild corticosteroid is sometimes prescribed for PIH that does not respond to single agents.
Vigorous sun protection. UV exposure worsens PIH and prolongs resolution. Visible light may also contribute to pigmentation in dark skin — tinted sunscreens with iron oxides provide broader protection than non-tinted formulations. Daily SPF 30+ is non-negotiable during PIH treatment.
Who should not be treated
Some patients should not undergo laser resurfacing regardless of wavelength or settings:
Isotretinoin within the past 6–12 months. Isotretinoin impairs wound healing and increases scarring risk. Most protocols require a minimum 6-month washout, and many providers prefer 12 months before performing any resurfacing procedure.
Active skin infections. Bacterial, viral (especially herpes simplex), or fungal infections at the treatment site must be resolved before laser treatment. Fractional resurfacing creates open channels in the skin that can disseminate infection.
History of keloids. Keloid scarring is a relative contraindication. Patients who form keloids in response to skin injury may form them in response to laser injury, particularly with ablative devices. Non-ablative fractional lasers, which preserve the epidermis, carry lower keloid risk and may be considered in select patients.
Recent sun exposure or tanning. Sun-stimulated melanocytes are more reactive and more likely to produce PIH. Any recent tanning or significant sun exposure should delay treatment until the skin has returned to its baseline pigmentation — typically 4–6 weeks.
Unrealistic expectations. Laser resurfacing in dark skin requires conservative settings, which means more sessions for incremental improvement. Patients expecting dramatic results from a single session will be disappointed and may pressure the provider to increase aggressiveness beyond what is safe.
Provider selection
The device matters. The settings matter. But the variable that matters most is the person holding the handpiece. A board-certified dermatologist or plastic surgeon who has specific training and ongoing experience treating Fitzpatrick IV–VI skin will choose the right wavelength, adjust settings for the individual patient, use test spots, implement pre-treatment protocols, and recognize early PIH before it becomes a management problem. A provider who primarily treats lighter skin and occasionally sees a patient with dark skin may use the same settings that work for their typical patient — and those settings may cause harm.
What to ask:
"How many patients with my skin type have you treated with laser resurfacing?" The answer should be specific and reflect ongoing experience, not a handful of cases years ago.
"What wavelength and device will you use, and why is it appropriate for my skin?" The answer should reference the wavelength, why it is safer for dark skin, and what the alternatives are. If the answer is just "we use this device for everyone," that is a concern.
"What density and fluence will you start with, and will you do a test spot?" Lower density and conservative fluence are standard for Fitzpatrick IV–VI. A test spot is prudent, especially for a first treatment.
"What pre-treatment protocol will I follow?" Hydroquinone and sun protection for 2–4 weeks before treatment should be standard for Fitzpatrick V–VI. If no pre-treatment is mentioned, ask why.
"What happens if I develop PIH?" The plan should include topical therapy initiated promptly, follow-up scheduling, and a realistic timeline. "It will fade on its own" is not a plan.
Sources
Alexis AF, Coley MK, Nijhawan RI, et al. "Nonablative fractional laser resurfacing for acne scarring in patients with Fitzpatrick skin phototypes IV–VI." Dermatologic Surgery. 2016;42:392–402. https://pubmed.ncbi.nlm.nih.gov/26945321/
StatPearls. "Laser Fitzpatrick Skin Type Recommendations." NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK557626/
Sheppard T, Quiñonez RL, Burgess CM, Taylor SC, Agbai O. "Noninvasive Cosmetic Treatments for Fitzpatrick IV–VI: A Narrative Review of Safety and Efficacy Guidelines." PMC. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC13012588/
Aggarwal I, Rossi M, Tsoukas M. "Review of Fractional Nonablative Lasers for the Treatment of Dermatologic Conditions in Darker Skin Phototypes." Dermatologic Surgery. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC12997392/
Battle EF Jr, Hobbs LM. "Laser therapy on darker ethnic skin." Dermatologic Clinics. 2003;21:713–723.
Alexis AF. "Fractional lasers for acne scarring in patients with skin of color." Cutis. 2017. https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/024110508.pdf
ClinicalTrials.gov. "Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color." NCT05362929. https://clinicaltrials.gov/study/NCT05362929
AAD. "How to fade dark spots in darker skin tones." https://www.aad.org/public/everyday-care/skin-care-secrets/routine/fade-dark-spots
